Tuesday, US regulators recommended halting use of the Johnson & Johnson vaccine due to blood clotting concerns. 

“Right now, these adverse events appear to be extremely rare,” the FDA said in a joint statement with the Centers for Disease Control and Prevention (CDC).

“COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously.”

Six cases of blood clotting were reported in women ages 18-48. 

The European Medicines Agency is investigating a similar issue. 

This is a developing story.